Oncolytic viruses (OVs) are able to selectively infect and kill cancer cells without damaging normal cells. They can be used as a monotherapy, or they can be combined with existing cancer therapeutics for increased potency. While much progress has been made around OVs, one of their biggest limitations is their inability to successfully replicate, spread,...

Nanoarray-based assays offer advantages over standard microarray assays such as minimal sample consumption, high efficiency, and enhanced multiplexing capacity. However, despite their potential, they face challenges such as the complexity and high cost of spotting and fabrication, as well as a lack of effective detection schemes. This impedes many practical...

Chimeric antigen receptor (CAR)-T-cell-based immunotherapies have dramatically improved survival in cancer patients. Unfortunately, CAR-T cell therapies are associated with severe neurotoxicity, adverse events during clinical trials, and cytokine storm syndrome among others. Therefore, there is a great need to develop strategies that can keep the benefits...

There is a great need to deliver metabolites intracellularly without modifying the metabolite itself and rescue immune cells against metabolic exhaustion. In cancer therapy, metabolic pathway inhibitors are used that starve both cancerous cells as well as non-cancerous cells. Therefore, the ability to target specific immune cells and deliver metabolites...

Inhibition of glycolysis or glutaminase pathway is an effective strategy to prevent cancer cell growth in vitro and in vivo. However, these pathways are also utilized by immune cells to mount responses against cancer cells, and therefore, utilizing, immunotherapies in the presence of such inhibitors is challenging. Thus, there is a need for technologies...

There is a rich history of successful drug delivery carriers made of biodegradable biomaterials. Biomaterials may degrade into metabolic by-products, which are capable of modulating the function of immune cells, including alpha-ketoglutarate (aKG), which induces alternative activation (immunosuppressive phenotype) in macrophages through metabolic reprogramming....

Glycolysis inhibition in cancer cells has long been recognized as a viable strategy to prevent cancer cell growth. Cancer cells are known to have a high glucose consumption rate as a metabolism adaptation mechanism called the Warburg effect. Activated immune cells also rely on glycolysis for their energy needs. For example, glycolysis is essential for...

M23-139L – Inducing or Rescuing Glycolysis in Cancer Cells. Compositions that selectively block glycolysis in cancer cells while simultaneously enable glycolysis in non-cancer cells, such as macrophages, T cells, NK cells, etc. Vaccine formulations have been developed and tested on mice with positive results. Please see the published PCT (WO2024151709A1)...

Short-chain fatty acids (SCFAs) which include acetate (C2), propionate (C3) and butyrate (C4) are important, health-benefiting metabolites, produced when microbes in the human colon ferment polysaccharides and dietary fiber. Medium-chain fatty acids (MCFAs), such as caproate (C6) and caprylate (C8), have also been shown to provide health benefits and...

The amount of time and money that goes into getting a drug from initial discovery to FDA approval is substantial, typically involving at least 10 years and hundreds of millions of dollars. Because of this, there has been a growing interest in repurposing drugs which have previously been approved for human use, particularly since their MOA as well as...